emirates7 - The 13th International Pharmacy and Medicine Conference (ICPM 2025) announced the establishment of three new pharmaceutical factories in Sharjah, representing a total investment of over $84 million (AED 308.7 million).
The agreements for these projects were formalized during the event held at the Sharjah Research, Technology, and Innovation Park. These new facilities will complement an existing pharmaceutical plant in Sharjah, further advancing the region's pharmaceutical sector.
The factories are set to manufacture a range of products, including respiratory treatments, eye drops, antibiotic capsules, gastrointestinal medications, and first aid supplies. Construction is currently in progress, with all facilities scheduled for completion between mid and late 2026.
Dr. Munir Rayyan, Chairman of the Organising Committee, emphasized the importance of these developments in enhancing collaboration between global pharmaceutical companies and UAE-based manufacturers. He also highlighted their role in strengthening the UAE's position in the regional pharmaceutical market.
The first factory, with an investment of $44 million, will specialize in eye drops and respiratory treatments, employing state-of-the-art technology. It is expected to be completed by the end of 2026.
The second facility, requiring a $35 million investment and spanning 10,000 square feet, will focus on producing antibiotic capsules and gastrointestinal medications. It will have an annual production capacity of 600 million capsules, with operations anticipated to begin in 2026.
The third project, valued at $5 million, will concentrate on first aid products. Construction is slated to commence later this year, with completion anticipated by early 2025.
These factories underscore the UAE’s growing prominence in pharmaceutical innovation and its competitive standing in the global healthcare sector.
The agreements for these projects were formalized during the event held at the Sharjah Research, Technology, and Innovation Park. These new facilities will complement an existing pharmaceutical plant in Sharjah, further advancing the region's pharmaceutical sector.
The factories are set to manufacture a range of products, including respiratory treatments, eye drops, antibiotic capsules, gastrointestinal medications, and first aid supplies. Construction is currently in progress, with all facilities scheduled for completion between mid and late 2026.
Dr. Munir Rayyan, Chairman of the Organising Committee, emphasized the importance of these developments in enhancing collaboration between global pharmaceutical companies and UAE-based manufacturers. He also highlighted their role in strengthening the UAE's position in the regional pharmaceutical market.
The first factory, with an investment of $44 million, will specialize in eye drops and respiratory treatments, employing state-of-the-art technology. It is expected to be completed by the end of 2026.
The second facility, requiring a $35 million investment and spanning 10,000 square feet, will focus on producing antibiotic capsules and gastrointestinal medications. It will have an annual production capacity of 600 million capsules, with operations anticipated to begin in 2026.
The third project, valued at $5 million, will concentrate on first aid products. Construction is slated to commence later this year, with completion anticipated by early 2025.
These factories underscore the UAE’s growing prominence in pharmaceutical innovation and its competitive standing in the global healthcare sector.